GRACE :: Lung Cancer

Search cancerGRACE.org

Current Clinical Trials

GRACE Video

The Lung Cancer Master Protocol/SWOG 1400 as a Clinical Trial for a New Era of Molecular Oncology

Share

LCAM 2015

 

Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an “umbrella protocol” in which all patients undergo molecular testing and have treatment assigned by the results.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

Get more information about the Lung-MAP Trial.

How Did You Like This Video?

Check out more LCAM videos & posts here.


GRACE Video

Clinical Trial Spotlight: Can Epigenetic Priming Improve Efficacy of Immunotherapy in NSCLC?

Share

LCAM 2015

 

Dr. Jack West reviews the concept of epigenetics, epigenetic priming, and whether oral azacytidine can improve outcomes in patients who receive immunotherapy for advanced lung cancer.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

How Did You Like This Video?

Check out more LCAM videos & posts here.


GRACE Video

Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

Share

LCAM 2015

 

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

Get more information about the TH4000 Trial.

How Did You Like This Video?

Check out more LCAM videos & posts here.


GRACE Video

Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLC

Share

LCAM 2015

 

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

Get more information about the IMpower-110 Trial and CheckMate-227 Trial.

How Did You Like This Video?

Check out more LCAM videos & posts here.


Many Clinical Trial Options Exist for Small Cell Lung Cancer Patients

Share

Small cell lung cancer (SCLC) patients badly need new treatment options because the ones they have have not changed in almost 40 years. But a renewed interest in SCLC has led to an increase in research and the development of clinical trials testing new drugs. The links below beginning with “NCT” (National Clinical Trial) will provide more information that you can take to your doctor.

- Alisertib, an aurora kinase A inhibitor, is being studied with paclitaxel in the second line (NCT02038647); early trials using the drug showed activity and in particular, pre-clinical work has shown that tumors with MYC alterations may be most sensitive to Aurora Kinase inhibitors.

- Fibroblast growth factor receptor 1 (FGFR1) is amplified in 6% of small cell lung cancer and there are clinical studies evaluating drugs targeting the FGFR family members for SCLC patients, including the experimental drug JNJ 42756493 (NCT01703481).

- SCLC is known to have many abnormalities in DNA damage repair proteins and genes. One protein being studied is PARP, which is over-expressed in SCLC. There are active studies evaluating the PARP inhibitors, talazoparib and veliparib either alone or in combination with chemotherapy for the treatment of SCLC (NCT01286987, NCT01642251, NCT02289690, and NCT01638546). Olaparib, another PARP inhibitor, is being evaluated with temozolomide in the setting of a phase II clinical trial (NCT02446704).

The immune checkpoint inhibitors, nivolumab and pembrolizumab, have been FDA-approved for the treatment of non-small cell lung cancer. Early studies using these agents in SCLC have showed encouraging and prolonged response rates.  There are numerous studies using immune checkpoint inhibitors that are currently open or about to launch. These drugs are being studied as:

- Maintenance treatment (NCT02538666 and NCT02359019);
- In the second line setting (NCT02481830);
- With radiation therapy (NCT02402920); or
- After several lines of therapy (NCT01928394NCT02261220, and NCT02472977).

Recently, results from a phase I/Ib study showed impressive activity in the second- and third- line setting for an antibody drug conjugate, rovalpituzumab tesirine, especially in the subset of patients whose tumors had high expression of the delta-like protein 3, which the drug targets. Phase II studies with rovalpituzumab tesirine are planned and likely will be available in 2016. A phase I study evaluating a similar compound is actively recruiting patients (NCT02500914).  

The studies highlighted above do not represent an inclusive list, but they do show that there are many trials searching for better answers for small cell lung cancer. Hopefully, the findings from these studies will begin to change the prognosis for patients with this disease. 

Please consider a clinical trial at some point during your treatment.

 


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243